| Study, Year | Outcomes Measure | Unit | Description of Intervention | n Final Control n Final Intervention | Control Outcome Measure at Baseline Intervention Outcome Measure at Baseline | Control Outcome Measure at Final Intervention Outcome Measure at Final | Control Change Intervention Change | Change Difference Final Difference | P-Value |
|--------------|---|------------|--|--------------------------------------|--|--|---|---|---------|
| Frosch, 2008 | Total knowledge score/imputed data | Score unit | Traditional didactic decision aid providing information about prostate-specific antigen (PSA) screening options and outcomes vs. Links to public prostate cancer— specific Web sites from credible sources | 116 155 | | 7.24 8.14 | | 0.9 | 0.005 |
| | Total knowledge score/complete cases only | Score unit | Traditional didactic decision aid providing information about prostate-specific antigen (PSA) screening options and outcomes vs. Links to public prostate cancer— specific Web sites from credible sources | 119 | | 8.65 | | 1.16 | 0.001 |
| | Total knowledge | Score unit | Chronic disease | 116 | | 7.24 | | | 0.005 |

| Study, Year | Outcomes Measure | Unit | Description of Intervention | n Final Control n Final Intervention | Control Outcome Measure at Baseline Intervention Outcome Measure at Baseline | Control Outcome Measure at Final Intervention Outcome Measure at Final | Control Change Intervention Change | Change Difference Final Difference | P-Value |
|-------------|---|------------|---|---|--|--|---|---|---------|
| | score/imputed data | | trajectory model for prostate cancer followed by a time—trade- off exercise vs. Links to public prostate cancer— specific Web sites from credible sources | 153 | | 7.69 | V | 0.45 | |
| | Total knowledge score/complete cases only | Score unit | Chronic disease trajectory model for prostate cancer followed by a time—tradeoff exercise vs. Links to public prostate cancer—specific Web sites from credible sources | 99 115 | | 7.49 8.03 | | 0.54 | 0.001 |
| | Total knowledge score/imputed data Total knowledge | Score unit | Both the didactic decision aid and the chronic disease trajectory model vs. Links to public prostate cancer—specific Web sites from credible sources Both the didactic | 116 152 | | 7.24 7.71 | | 0.47 | 0.005 |

| Outcomes Measure | Unit | Description of Intervention | n Final Control n Final Intervention | Control Outcome Measure at Baseline Intervention Outcome Measure at Baseline | Control Outcome Measure at Final Intervention Outcome Measure at Final | Control Change Intervention Change | Change Difference Final Difference | P-Value |
|----------------------------------|--|--|--|---|---|--|---|--|
| score/complete cases only | | decision aid and the chronic disease trajectory model vs. Links to public prostate cancer—specific Web sites from credible sources | 117 | | 8.03 | | 0.54 | |
| PSA screening: Pretest choice | %% of patients with outcome | Traditional didactic decision aid providing information about prostate-specific antigen (PSA) screening options and outcomes vs. Links to public prostate cancer— specific Web sites from credible | 116 | | 96 95.5 | | -0.5 | **SNR |
| PSA screening: Reduction | % of patients with outcome | Traditional didactic decision aid providing information about prostate-specific antigen (PSA) screening options and outcomes vs. Links to public prostate cancer— specific Web sites from credible sources | 116 155 | | 3.3 9.1 | | 5.8 | 0.047 |
| | Measure score/complete cases only PSA screening: Pretest choice PSA screening: Reduction | Measure score/complete cases only PSA screening: Pretest choice PSA screening: with outcome PSA screening: Reduction % of patients with outcome | Measure Unit Intervention score/complete cases only decision aid and the chronic disease trajectory model vs. Links to public prostate cancer—specific Web sites from credible sources PSA screening: Pretest choice %% of patients with outcome Traditional didactic decision aid providing information about prostate-specific antigen (PSA) screening options and outcomes vs. Links to public prostate cancer—specific Web sites from credible sources PSA screening: Reduction % of patients with outcome Traditional didactic decision aid providing information about prostate-specific antigen (PSA) screening options and outcomes vs. Links to public prostate cancer—specific Web sites from credible sources | Outcomes Measure Unit Description of Intervention Control score/complete cases only decision aid and the chronic disease trajectory model vs. Links to public prostate cancer—specific Web sites from credible sources 117 PSA screening: Pretest choice %% of patients with outcome Traditional didactic decision aid providing information about prostate-specific antigen (PSA) screening options and outcomes vs. Links to public prostate cancer—specific Web sites from credible sources 116 PSA screening: Reduction % of patients with outcome Traditional didactic decision aid providing information about prostate cancer—specific web sites from credible sources 116 PSA screening: Reduction % of patients with outcome Traditional didactic decision aid providing information about prostate-specific antigen (PSA) screening options and outcomes vs. Links to public prostate cancer—specific Web sites from credible sources 155 | Outcomes Measure Unit Description of Intervention score/complete cases only PSA screening: Pretest choice PSA screening: Reduction PSA screening: Reduction Reduction PSA screening: PSA screening: Reduction Reduction PSA screening: PSA screening: Reduction Reduction Description of Intervention Intervention decision aid and the chronic disease trajectory model vs. Links to public prostate cancer—specific Web sites from credible sources Traditional didactic decision aid providing information about prostate-specific antigen (PSA) screening options and outcomes vs. Links to public prostate cancer—specific Web sites from credible sources PSA screening: Reduction PSA screening: Reduction Reduction | Outcomes Measure Score/complete cases only PSA screening: Pretest choice PSA screening: Reduction PSA screening: Reduct | Outcomes Outcomes Outcome Description of Intervention Intervention Intervention Outcome Measure at Baseline Intervention Intervention Outcome Measure at Intervention Intervention Outcome Measure at Baseline Intervention Outcome Measure at Baseline Intervention Intervention Intervention Outcome Measure at Baseline Intervention Intervention | Outcomes Measure Unit Description of Intervention Score/complete cases only Served in the chronic disease trajectory model vs. Links to public prostate cancer—specific with outcome PSA screening: Pretest choice PSA screening: PSA screening: Pretest choice PSA screening: Pretest choice PSA screening: PSA s |

| Study, Year | Outcomes Measure | Unit | Description of Intervention | n Final Control n Final Intervention | Control Outcome Measure at Baseline Intervention Outcome Measure at Baseline | Control Outcome Measure at Final Intervention Outcome Measure at Final | Control Change Intervention Change | Change Difference Final Difference | P-Value |
|---|----------------------------------|-----------------------------|--|---|--|--|---|---|---------|
| ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | at pretest | patients with outcome | didactic decision aid providing information about prostate-specific antigen (PSA) screening options and outcomes vs. Links to public prostate cancer— specific Web sites from credible sources | 155 | | 34.2 | 3 | -0.2 | |
| | PSA screening: Pretest choice | % of patients with outcome | Chronic disease trajectory model for prostate cancer followed by a time—trade-off exercise vs. Links to public prostate cancer—specific Web sites from credible sources | 116 153 | | 96 96.7 | | 0.7 | **SNR |
| | PSA screening: Reduction | % of patients with outcome | Chronic disease trajectory model for prostate cancer followed by a time—tradeoff exercise vs. Links to public prostate cancer—specific Web sites from credible sources | 116 153 | | 3.3 8.7 | | 5.4 | 0.047 |

| Study, Year | Outcomes Measure | Unit | Description of Intervention | n Final Control n Final Intervention | Control Outcome Measure at Baseline Intervention Outcome Measure at Baseline | Control Outcome Measure at Final Intervention Outcome Measure at Final | Control Change Intervention Change | Change Difference Final Difference | P-Value |
|-------------|----------------------------------|-----------------------------|---|--------------------------------------|--|--|---|---|---------|
| | at pretest | patients with outcome | trajectory model for prostate cancer followed by a time—trade- off exercise vs. Links to public prostate cancer— specific Web sites from credible sources | 153 | | 34 | | -0.4 | |
| | PSA screening: Pretest choice | % of patients with outcome | Both the didactic decision aid and the chronic disease trajectory model vs. Links to public prostate cancer—specific Web sites from credible sources | 116 152 | | 96 96.7 | | 0.7 | **SNR |
| | PSA screening: Reduction | % of patients with outcome | Both the didactic decision aid and the chronic disease trajectory model vs. Links to public prostate cancer—specific Web sites from credible sources | 116 152 | | 3.3 5.3 | | 2 | 0 |
| | Watchful waiting | % of | Web sites from | 116 | | 34.4 | | | |

| Study, Year | Outcomes Measure at pretest | Unit patients with | Description of Intervention decision aid and the chronic | n Final Control n Final Intervention | Control Outcome Measure at Baseline Intervention Outcome Measure at Baseline | Control Outcome Measure at Final Intervention Outcome Measure at Final 40.8 | Control Change Intervention Change | Change Difference Final Difference 6.4 | P-Value |
|----------------------------------|--|----------------------------|--|--------------------------------------|--|---|---|--|---------|
| | | outcome | disease trajectory model vs. Links to public prostate cancer–specific Web sites from credible sources | | | | | | |
| Gaertner,2004 | Patient satisfaction | Score unit | Use of electronic pain diary vs. Paper diary | 24 | | 10 | | 2 | - |
| | Patient preference for electronic diary (%) | % of patients with outcome | Use of electronic pain diary vs. Paper diary | 24 | | 17 | | 56 | |
| | Health care support | % of patients with outcome | Use of electronic pain diary vs. Paper diary | 24 | | 17 62 | | 45 | - |
| Glazebrook, 2006 ³ | Melanoma knowledge score (0-12) | Score unit | Skinsafe multimedia intervention (for melanoma knowledge protective skin behaviors) vs. No intervention | 245 214 | 2.75 | 3.03 | 0.28 | 0.53 | <0.001 |
| | Skin protective behavior score (0-12) | Score unit | Skinsafe multimedia intervention (for melanoma knowledge protective skin behaviors) vs. No intervention | 245 214 | 4.66 4.6 | 5.06 5.36 | 0.4 0.76 | 0.36 | <0.004 |

| Study, Year | Outcomes Measure Number of participants checking moles | Unit % of patients with outcome | Description of Intervention Skinsafe multimedia intervention (for melanoma knowledge protective skin behaviors) vs. No intervention | n Final Control n Final Intervention 245 214 | Control Outcome Measure at Baseline Intervention Outcome Measure at Baseline | Control Outcome Measure at Final Intervention Outcome Measure at Final 65.7 61.9 | Control Change Intervention Change | Change Difference Final Difference | P-Value 0.035 |
|---------------------------|---|---------------------------------|---|--|--|--|---|---|----------------------|
| Maslin, 1998 ⁴ | Viewing interactive video disk had impact on surgical choice | % of patients with outcome | Intervention interactive video disk system + usual care from multidisciplinary team vs. Usual care from multidisciplinary team | 49 51 | | no Data 12.5 | | *insufficient data | 0 |
| | Viewing interactive video disk had impact on adjuvant therapy choice | % of patients with outcome | Intervention interactive video disk system + usual care from multidisciplinary team vs. Usual care from multidisciplinary team | 49 51 | | no Data 14.2 | | *insufficient data | 0 |
| Ruland, 2003 ⁵ | Congruence between patient-reported symptoms and those addressed in consult visit | % of patients with outcome | Used computerized system for shared decision making for cancer symptoms care vs. Usual care | 25 27 | | 2.84 7.63 | | 4.79 | <0.01 |

| Study, Year | Outcomes Measure Importance- weighted congruence between patient-reported symptoms and those addressed in consult visit | Unit Congruence | Description of Intervention Used computerized system for shared decision making for cancer symptoms care vs. Usual care | n Final Control n Final Intervention 25 27 | Control Outcome Measure at Baseline Intervention Outcome Measure at Baseline | Control Outcome Measure at Final Intervention Outcome Measure at Final 12.8 33 | Control Change Intervention Change | Change Difference Final Difference | P-Value <0.01 |
|-------------------------------|---|--------------------|--|--|--|--|---|---|----------------------|
| Taenzer, 2000 ⁶ | Actions taken/- patient | Actions | Lung cancer patients whose physicians and nurses received Quality-of-Life training and patients completed the computerized European Organization For Research And Treatment Of Cancer QLQ-C30 vs. Patients completed a paper-and pencil version of the European Organization For Research And Treatment Of Cancer QLQ-C30 vs. Patients | 26 27 | | 0.5 | | 0.3 | 0 |
| | % of categories | % of | Treatment Of Cancer QLQ-C30 | 26 | | 64.7 | | | 0 |

| Study, Year | Outcomes Measure | Unit | Description of Intervention | n Final Control n Final Intervention | Control Outcome Measure at Baseline Intervention Outcome Measure at Baseline | Control Outcome Measure at Final Intervention Outcome Measure at Final | Control Change Intervention Change | Change Difference Final Difference | P-Value |
|-------------|---------------------------------|------------|---|--------------------------------------|--|--|---|---|---------|
| | identified that were acted upon | categories | patients whose physicians and nurses received Quality-of-Life training and patients completed the computerized European Organization For Research And Treatment Of Cancer QLQ-C30 vs. Patients completed a paper-and pencil version of the European | 27 | | 73 | | 8.3 | |
| | | | Organization For Research And Treatment Of Cancer QLQ-C30 only | | | | | | |

P-value of 0 = p-value > 0.10

EORTC QLQ: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, PSA: Prostate-specific antigen.

^{**}SNR: Significance not reported

Reference List

- 1 Frosch DL, Bhatnagar V, Tally S, Hamori CJ, Kaplan RM. Internet patient decision support: a randomized controlled trial comparing alternative approaches for men considering prostate cancer screening. Arch Intern Med 2008; 168(4):363-9.
- 2 Gaertner J, Elsner F, Pollmann-Dahmen K, Radbruch L, Sabatowski R. Electronic pain diary: a randomized crossover study. J Pain Symptom Manage 2004; 28(3):259-67.
- 3 Glazebrook C, Garrud P, Avery A, Coupland C, Williams H. Impact of a multimedia intervention "Skinsafe" on patients' knowledge and protective behaviors. Preventive Medicine 2006; 42(6):449-54.
- 4 Maslin A, Baum M, Walker J, A'Hern R, Prouse A. Shared decision-making using an interactive video disk system for women with early breast cancer... including commentary by Beaver K. NT Research 1998; 3(6):444-55.

- 5 Ruland CM, White T, Stevens M, Fanciullo G, Khilani SM. Effects of a computerized system to support shared decision making in symptom management of cancer patients: preliminary results.

 Journal of the American Medical Informatics Association:

 JAMIA 2003; 10(6):573-9.
- 6 Taenzer P, Bultz BD, Carlson LE *et al*. Impact of computerized quality of life screening on physician behaviour and patient satisfaction in lung cancer outpatients. Psychooncology 2000; 9(3):203-13.